A major shift in stroke care is underway as tenecteplase outperforms alteplase. This new treatment could redefine recovery ...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed ...

Necroptosis is the predominant form of neuronal death after ischemic stroke. This study identifies the deubiquitinating enzyme OTUB2 as a novel regulator of the RIPK1-RIPK3-MLKL necroptotic signaling ...

Lowering the body temperature of preterm infants (born at 33 to 35 weeks of pregnancy) with hypoxic ischemic encephalopathy ...

The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. <li /> Administered as a ...

Traditional Chinese medicine (TCM) has attracted a great deal of attention in the treatment of cerebral ischemia is credited with the remarkable neuroprotective effects. However, the imperfect ...

and its scientific rationale in the Company’s ongoing Phase 2/3 trial for acute ischemic stroke (ReMEDy2 Trial). DM199, a bradykinin-producing enzyme, represents a promising potential treatment ...

musc.edu Introduction The direct aspiration first pass technique (ADAPT) has been introduced as a simple and fast method for achieving good angiographic and clinical outcomes using large bore ...

However, there were discrepancies in the statistical significance of the results between the propensity score matching and stabilized inverse probability of treatment weighting analysis. The results ...